Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)
PHASE3CompletedINTERVENTIONAL
Enrollment
1,274
Participants
Timeline
Start Date
October 30, 2014
Primary Completion Date
September 4, 2018
Study Completion Date
September 12, 2022
Conditions
Non-small Cell Lung Cancer
Interventions
BIOLOGICAL
pembrolizumab
DRUG
carboplatin
DRUG
paclitaxel
DRUG
pemetrexed
All Listed Sponsors
lead
Merck Sharp & Dohme LLC
INDUSTRY
NCT02220894 - Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042) | Biotech Hunter | Biotech Hunter